SlideShare a Scribd company logo
A Snapshot of Approved Therapies and
Ongoing Investigations in Urothelial Carcinoma
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40
DRUG/TARGET INDICATION DOSING
Approved for the treatment of adult pts with locally advanced UC or mUC who have previously
received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy in the
neoadjuvant/adjuvant, locally advanced, or metastatic setting
Approved for the treatment of pts with locally advanced UC or mUC who are ineligible for
cisplatin-containing chemotherapy and have received ≥1 prior line of therapy
Antibody–Drug Conjugates
Enfortumab vedotin6
Nectin-4
1.25 mg/kg (≤125 mg)
as IV infusion over
30 min on d 1, 8, and 15 of
a 28-d cycle until disease
progression or toxicity
Approved for the treatment of pts with locally advanced or metastatic disease
who are platinum ineligible
Approved for the treatment of pretreated pts with locally advanced UC or mUC who
progressed on prior platinum-based tx or relapsed within 1 y of perioperative
platinum-containing chemotherapy tx
Approved for the treatment of pts with BCG-unresponsive, high-risk NMIBC with CIS with
or without papillary tumors who are ineligible for or have elected not to undergo cystectomy
Pembrolizumab4
PD-1
200 mg every 3 wk
or 400 mg every 6 wk
240 mg every 2 wk
or 480 mg every 4 wk
Approved for the treatment of pretreated pts with locally advanced UC or mUC who
progressed on prior platinum-based tx or relapsed within 1 y of perioperative cisplatin tx
Approved for the adjuvant treatment of pts with UC who are at high risk of
recurrence after undergoing radical resection of UC
Nivolumab3
PD-1
Immune Checkpoint Inhibitors
Atezolizumab1
PD-L1
840 mg every 2 wk,
1,200 mg every 3 wk,
or 1,680 mg every 4 wk
Approved for the treatment of newly diagnosed pts with cisplatin-ineligible locally
advanced UC or mUC and PD-L1+ tumors (tumor-infiltrating ICs covering ≥5%
of the tumor area) or who are platinum ineligible
Companion diagnostic: Ventana PD-L1 (SP142) Assay
Approved for the treatment of pretreated pts with locally advanced UC or mUC who
progressed on prior platinum-based tx or relapsed within 1 y of perioperative
platinum-containing chemotherapy tx
Approved for maintenance treatment of pts with locally advanced UC
or mUC that has not progressed with first-line platinum-containing chemotherapy
Avelumab2
PD-L1
800 mg every 2 wk
Trop-2
10 mg/kg on d 1 and 8,
every 21 d until disease
progression or toxicity
Approved for the treatment of pts with locally advanced
UC or mUC who have had prior treatment with a PD-1 or PD-L1 inhibitor
and a platinum-containing chemotherapy regimen
Sacituzumab govitecan7
Approved for the treatment of pretreated pts with locally advanced UC or mUC who have
FGFR2 or FGFR3 genetic alterations and who progressed on prior platinum-based tx
or relapsed within 1 y of perioperative platinum-containing chemotherapy tx
Companion diagnostic: therascreen®
FGFR RGQ RT-PCR Kit
Erdafitinib5
FGFR
8 mg daily with
an increase
to 9 mg daily based on
PO4
levels and tolerability
at 14 to 21 d
FGFR Inhibitors
Therapeutic Targets, Indications, and Dosing Information
1. Tecentriq (atezolizumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034Orig1s042lbl.pdf. 2. Bavencio (avelumab) Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s005lbl.pdf. 3. Opdivo (nivolumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125554s097lbledt.pdf.
4. Keytruda (pembrolizumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s113lbl.pdf. 5. Balversa (erdafitinib) Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212018s001lbl.pdf. 6. Padcev (enfortumab vedotin-ejfv) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf.
7. Trodelvy (sacituzumab govitecan-hziy) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf. 8. www.clinicaltrials.gov.
Selected Ongoing Clinical Trials of Innovative Treatment
Options in Urothelial Carcinoma8
First-Line Metastatic Second-Line Metastatic
Bladder Preservation
Adjuvant MIBC
CheckMate -901 (NCT03036098) phase 3:
nivolumab + ipilimumab vs nivolumab
+ chemo vs chemo
NILE (NCT03682068) phase 3:
durvalumab + chemo ± tremelimumab
NCT04863885 phase 1/2:
ipilimumab + nivolumab combined with
sacituzumab govitecan for cisplatin-ineligible pts
vs chemo
NORSE (NCT03473743) phase 2:
erdafitinib + cetrelimab vs erdafitinib
THOR (NCT03390504) phase 3:
erdafitinib vs chemo vs pembrolizumab in pts
with selected FGFR mutations
TROPHY-U-01 (NCT03547973) phase 2:
sacituzumab govitecan
TROPiCS-04 (NCT04527991) phase 3:
sacituzumab govitecan vs chemo
NMIBC
Neoadjuvant
SunRISe-2 (NCT04658862) phase 3:
TAR-200 + cetrelimab vs gemcitabine/cisplatin
or RT
S1806 (NCT03775265) phase 3:
atezolizumab ± CRT in localized MIBC
AMBASSADOR (NCT03244384) phase 3:
pembrolizumab vs observation
IMvigor010 (NCT02450331) phase 3:
atezolizumab vs observation
ALBAN (NCT03799835) phase 3:
atezolizumab + BCG vs BCG
KEYNOTE-676 (NCT03711032) phase 3:
SunRISe-1 (NCT04640623) phase 2b:
TAR-200 + cetrelimab vs TAR-200 vs cetrelimab
pembrolizumab + BCG vs BCG
SWOG 1605 (NCT02844816) phase 2:
atezolizumab monotherapy
ENERGIZE (NCT03661320) phase 3:
nivolumab + chemo or nivolumab +
linrodostat (IDO1 inhibitor) + chemotherapy
→ immuno-oncology therapy after radical
cystectomy vs chemotherapy
KEYNOTE-866 (NCT03924856) phase 3:
Perioperative pembrolizumab +
neoadjuvant chemo vs perioperative placebo +
neoadjuvant chemo
NCT04209114 phase 3:
neoadjuvant and adjuvant nivolumab +
bempegaldesleukin vs nivolumab alone vs
SOC in pts with MIBC who are cisplatin ineligible
KEYNOTE-B15 (NCT04700124) phase 3:
pembrolizumab + enfortumab vedotin
NCT04241185 phase 3:
pembrolizumab + CRT in MIBC
A Snapshot of Approved Therapies and
Ongoing Investigations in Urothelial Carcinoma
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40
Guide to Managing Adverse Events Associated
With Therapies for Urothelial Carcinoma
Therapeutic Targets, Current Status/Indication, and Dosing Information
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40
• In general, checkpoint inhibitor therapy should be continued with close monitoring,
with the exception of some neurologic, hematologic, and cardiac toxicities
Minimal or no symptoms; diagnostic changes only
Grade 1
• Hold checkpoint inhibitor therapy for most grade 2 toxicities
• Consider resuming immunotherapy when symptoms and/or laboratory values
revert to grade 1 or lower
• Corticosteroids (initial dose of 0.5-1 mg/kg/d of prednisone or equivalent) may
be administered
Grade 3 toxicities
• Hold checkpoint inhibitor therapy
• Initiate high-dose corticosteroids (prednisone 1-2 mg/kg/d or methylprednisolone
IV 1-2 mg/kg/d)
• If symptoms do not improve with 48-72 hours of high-dose corticosteroids,
infliximab may be offered for some toxicities
• Taper corticosteroids over the course of at least 4-6 weeks
• When symptoms and/or laboratory values revert to grade 1 or lower, rechallenging
with immunotherapy may be offered; however, caution is advised, especially in
those patients with early-onset irAEs; dose adjustments are not recommended
Grade 4 toxicities
• In general, permanent discontinuation of checkpoint inhibitor therapy is warranted,
with the exception of endocrinopathies that have been controlled by hormone
replacement
Grade 2
Mild to moderate symptoms
Severe or life-threatening symptoms
Grades 3/4
Immune checkpoint inhibitors are associated with important clinical
benefits, but general immunologic enhancement can also lead to a
unique spectrum of immune-related adverse events (irAEs)1,2
irAEs are often diagnosed by
exclusion; other causes should
be ruled out (including AEs of
other therapies used), but
immunotherapy-related toxicity
should always be included
in the differential
There should be a high level of
suspicion that new symptoms
are treatment related; early
recognition, evaluation, and
treatment of irAEs plus patient
education are essential for
best outcomes
Depending on the severity
of irAEs, management may
require corticosteroid or
other immunosuppressive
treatment as well as
interruption or
discontinuation of therapy
If appropriate,
immunosuppressive
treatment is used; patients
generally recover from irAEs
How should irAEs be diagnosed?
What are the general recommendations
for irAE management?
What is the spectrum of potential irAEs?
Pancreatitis,
autoimmune diabetes
Colitis
Enteritis
Encephalitis, aseptic meningitis
Thyroiditis, hypothyroidism,
hyperthyroidism
Dry mouth, mucositis
Hypophysitis
Uveitis
Pneumonitis
Thrombocytopenia,
anemia
Hepatitis
Adrenal insufficiency
Nephritis
Vasculitis
Arthralgia
Neuropathy
Rash, vitiligo
Myocarditis
Any organ system can be affected; commonly occurring irAEs are pulmonary
(pneumonitis), dermatologic (rash, pruritus, blisters, ulcers, vitiligo),
gastrointestinal (diarrhea, enterocolitis, transaminitis, hepatitis, pancreatitis),
and endocrine (thyroiditis, hypophysitis, adrenal insufficiency)
Why do
irAEs occur?
“Taking the brakes off”
of the immune system can
help the body fight cancer,
but it can also lead to
toxicity from a
“supercharged”
immune system.
Safety Management for
FGFR Inhibitor Therapy8,9
Erdafitinib
 Mucositis, other oral toxicities
Oral
 Monitor for toxicities
 Refer to dermatology and
podiatry as needed
Skin and Nail
 Dietary phosphate may require
restriction
 Individualized dietary plan
from nutrition professional
 Consider adding a
non–calcium-containing
phosphate binder (eg,
sevelamer carbonate)
Dietary
FGF FGF
FGF
FGF
FGFR
HSPG
FGF FGF
FGFRL1
SEF
SPRY
FRS2
PLC-y
DAG STAT
GAB1
SOS
GRB2
RAS RAF
MEK
ERK MKP3
MKP1
AKT
PKC
PI3K
Nucleus
Transcription of
target genes
Cytoplasm
Extracellular
PIP2
P
P
P
P
P
P
P
P
P
P
P
P
IP3
Plasma membrane
Proliferation
and survival
Resistance to
anticancer agents
Neoangiogenesis
FGFR alterations:
Amplification (receptor
overexpression) or
mutation/translocation
(ligand-independent
signaling)
FGF ligand:
Amplification
(autocrine) or
ECM/stromal-
cell release
(paracrine)
FGFR in UC3,4
FGFR Signaling Pathway7
FGFR is altered in 15% to 20% of advanced UC.5
Mutated FGFR3 is present in 37% of upper-tract UC.6
FGFRs are a family of receptor tyrosine kinases that are upregulated in multiple different cancers
and are involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell
survival; alterations in the FGFR gene, such as mutations and translocations, have been implicated
in the pathogenesis of UC
 Eye exams
 Withhold for any occurrence of
CSR or RPED
 Discontinue permanently if CSR/
RPED symptoms do not resolve
in 4 wk or if they escalate to grade 4
Ocular
Guide to Managing Adverse Events Associated
With Therapies for Urothelial Carcinoma
Therapeutic Targets, Current Status/Indication, and Dosing Information
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40
Sacituzumab Govitecan
Antibody–Drug Conjugates
Antibody–drug conjugates (ADCs) are molecules composed of an antibody chosen based on its ability to target a
tumor-specific protein linked to a cytotoxic payload or drug, enabling it to deliver a cytotoxic agent directly to the
targeted cells while minimizing toxicity to healthy cells10
Enfortumab Vedotin
Peripheral Neuropathy
 Generally resolves/remains at grade 1
Hyperglycemia
 Monitor blood glucose (patients with/at risk for
diabetes or hyperglycemia)
Maculopapular Diffuse Rash
 Topical steroids
 Antihistamines
 Dose reductions/delays
 Systemic corticosteroids (special cases)
Diarrhea
 Educate patients
 Hydration with electrolytes
 Anti-diarrheal medications
 Best supportive care
Safety Management for Antibody–Drug
Conjugate Therapy11-13
1Binds to
antigen
2Complex is internalized
and traffics to lysosome
3Payload is released
and causes cell death
Neutropenia
 Consider growth factor support
 Dose reduction or hold
Sacituzumab Govitecan
Enfortumab Vedotin
Target: Nectin-4, a type 1 transmembrane cell
adhesion molecule overexpressed in epithelial cancers
Linker: Protease cleavable
Payload: MMAE
Target: Trop-2, an epithelial cell-surface glycoprotein
highly expressed in muscle-invasive disease
Linker: Hydrolysable
Payload: SN-38, the active metabolite of irinotecan
1. Postow MA et al. N Engl J Med. 2018;378:158-168. 2. Brahmer JR et al. J Clin Oncol. 2018;36:1714-1768. 3. https://tcga-data.nci.nih.gov/docs/publications/tcga.
4. Knowles MA et al. Nat Rev Cancer. 2015;15:25-41. 5. Rodriguez-Vida A et al. J Hematol Oncol. 2015;8:119. 6. Li Q et al. Curr Urol Rep. 2016;17:12. 7. Touat M et al. Clin Cancer Res. 2015;21:2684-2694.
8. Loriot Y et al. N Engl J Med. 2019;381:338-348. 9. Balversa (erdafitinib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212018s001lbl.pdf. 10. Parslow AC et al.
Biomedicines. 2016;4:14. 11. Rosenberg JE et al. J Clin Oncol. 2019;37:2592-2600. 12. Loriot Y et al. Ann Oncol. 2020;31(suppl 4)s1142-s1215. 13. Petrylak DP et al. J Clin Oncol. 2020;38(suppl): Abstract 5027.
Guide to Managing Adverse Events Associated
With Therapies for Urothelial Carcinoma
Therapeutic Targets, Current Status/Indication, and Dosing Information
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40

More Related Content

Similar to Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies

Covid19 mgh treatment guidance 031820
Covid19 mgh treatment guidance 031820Covid19 mgh treatment guidance 031820
Covid19 mgh treatment guidance 031820
Freddy Flores Malpartida
 
Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor ...
Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor ...Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor ...
Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor ...
PVI, PeerView Institute for Medical Education
 
Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning...
Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning...Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning...
Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning...
PVI, PeerView Institute for Medical Education
 
02.02 adult art initiation gsn
02.02 adult  art initiation gsn02.02 adult  art initiation gsn
02.02 adult art initiation gsnDavid Ngogoyo
 
Endocrine_therapy.ppt
Endocrine_therapy.pptEndocrine_therapy.ppt
Endocrine_therapy.ppt
DoQuyenPhan1
 
03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiatDavid Ngogoyo
 
Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung ...
Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung ...Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung ...
Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung ...
PVI, PeerView Institute for Medical Education
 
Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances a...
Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances a...Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances a...
Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances a...
PVI, PeerView Institute for Medical Education
 
A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant an...
A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant an...A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant an...
A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant an...
PVI, PeerView Institute for Medical Education
 
Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making t...
Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making t...Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making t...
Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making t...
PVI, PeerView Institute for Medical Education
 
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
PVI, PeerView Institute for Medical Education
 
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...
PVI, PeerView Institute for Medical Education
 
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Care
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive CareRecurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Care
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Care
i3 Health
 
Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GE...
Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GE...Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GE...
Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GE...
PVI, PeerView Institute for Medical Education
 
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
hivlifeinfo
 
Inmnoterapia en cáncer urológico - Lo que el urólogo debe saber
Inmnoterapia en cáncer urológico - Lo que el urólogo debe saberInmnoterapia en cáncer urológico - Lo que el urólogo debe saber
Inmnoterapia en cáncer urológico - Lo que el urólogo debe saber
Mauricio Lema
 
Anti retroviral therapy in children
Anti retroviral therapy  in childrenAnti retroviral therapy  in children
Anti retroviral therapy in children
subhash chettri
 
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...
PVI, PeerView Institute for Medical Education
 
Pr. Peivand Pirouzi - Dr. Hamid Reza Bokaee Research Project Presentation 2015
Pr. Peivand Pirouzi - Dr. Hamid Reza  Bokaee Research Project Presentation 2015Pr. Peivand Pirouzi - Dr. Hamid Reza  Bokaee Research Project Presentation 2015
Pr. Peivand Pirouzi - Dr. Hamid Reza Bokaee Research Project Presentation 2015
Pharmaceutical Compliance Inspection unit, Crown College of Canada
 
Nivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCCNivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCCAbdelrahman Labban
 

Similar to Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies (20)

Covid19 mgh treatment guidance 031820
Covid19 mgh treatment guidance 031820Covid19 mgh treatment guidance 031820
Covid19 mgh treatment guidance 031820
 
Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor ...
Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor ...Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor ...
Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor ...
 
Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning...
Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning...Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning...
Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning...
 
02.02 adult art initiation gsn
02.02 adult  art initiation gsn02.02 adult  art initiation gsn
02.02 adult art initiation gsn
 
Endocrine_therapy.ppt
Endocrine_therapy.pptEndocrine_therapy.ppt
Endocrine_therapy.ppt
 
03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat
 
Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung ...
Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung ...Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung ...
Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung ...
 
Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances a...
Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances a...Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances a...
Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances a...
 
A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant an...
A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant an...A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant an...
A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant an...
 
Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making t...
Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making t...Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making t...
Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making t...
 
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
 
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...
 
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Care
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive CareRecurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Care
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Care
 
Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GE...
Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GE...Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GE...
Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GE...
 
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
 
Inmnoterapia en cáncer urológico - Lo que el urólogo debe saber
Inmnoterapia en cáncer urológico - Lo que el urólogo debe saberInmnoterapia en cáncer urológico - Lo que el urólogo debe saber
Inmnoterapia en cáncer urológico - Lo que el urólogo debe saber
 
Anti retroviral therapy in children
Anti retroviral therapy  in childrenAnti retroviral therapy  in children
Anti retroviral therapy in children
 
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...
 
Pr. Peivand Pirouzi - Dr. Hamid Reza Bokaee Research Project Presentation 2015
Pr. Peivand Pirouzi - Dr. Hamid Reza  Bokaee Research Project Presentation 2015Pr. Peivand Pirouzi - Dr. Hamid Reza  Bokaee Research Project Presentation 2015
Pr. Peivand Pirouzi - Dr. Hamid Reza Bokaee Research Project Presentation 2015
 
Nivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCCNivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCC
 

More from PVI, PeerView Institute for Medical Education

Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
PVI, PeerView Institute for Medical Education
 
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
PVI, PeerView Institute for Medical Education
 
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
PVI, PeerView Institute for Medical Education
 
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
PVI, PeerView Institute for Medical Education
 
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
PVI, PeerView Institute for Medical Education
 
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
PVI, PeerView Institute for Medical Education
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
PVI, PeerView Institute for Medical Education
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
PVI, PeerView Institute for Medical Education
 
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
PVI, PeerView Institute for Medical Education
 
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
PVI, PeerView Institute for Medical Education
 
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
PVI, PeerView Institute for Medical Education
 
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
PVI, PeerView Institute for Medical Education
 
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
PVI, PeerView Institute for Medical Education
 
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
PVI, PeerView Institute for Medical Education
 
Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remissi...
Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remissi...Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remissi...
Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remissi...
PVI, PeerView Institute for Medical Education
 
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
PVI, PeerView Institute for Medical Education
 
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
PVI, PeerView Institute for Medical Education
 
Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Stra...
Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Stra...Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Stra...
Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Stra...
PVI, PeerView Institute for Medical Education
 
Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy...
Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy...Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy...
Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy...
PVI, PeerView Institute for Medical Education
 
BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Tr...
BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Tr...BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Tr...
BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Tr...
PVI, PeerView Institute for Medical Education
 

More from PVI, PeerView Institute for Medical Education (20)

Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
 
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
 
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
 
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
 
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
 
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
 
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
 
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
 
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
 
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
 
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
 
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
 
Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remissi...
Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remissi...Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remissi...
Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remissi...
 
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
 
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...
 
Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Stra...
Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Stra...Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Stra...
Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Stra...
 
Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy...
Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy...Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy...
Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy...
 
BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Tr...
BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Tr...BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Tr...
BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Tr...
 

Recently uploaded

How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 

Recently uploaded (20)

How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 

Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies

  • 1. A Snapshot of Approved Therapies and Ongoing Investigations in Urothelial Carcinoma Full abbreviations, accreditation, and disclosure information available at PeerView.com/RPD40 DRUG/TARGET INDICATION DOSING Approved for the treatment of adult pts with locally advanced UC or mUC who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting Approved for the treatment of pts with locally advanced UC or mUC who are ineligible for cisplatin-containing chemotherapy and have received ≥1 prior line of therapy Antibody–Drug Conjugates Enfortumab vedotin6 Nectin-4 1.25 mg/kg (≤125 mg) as IV infusion over 30 min on d 1, 8, and 15 of a 28-d cycle until disease progression or toxicity Approved for the treatment of pts with locally advanced or metastatic disease who are platinum ineligible Approved for the treatment of pretreated pts with locally advanced UC or mUC who progressed on prior platinum-based tx or relapsed within 1 y of perioperative platinum-containing chemotherapy tx Approved for the treatment of pts with BCG-unresponsive, high-risk NMIBC with CIS with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy Pembrolizumab4 PD-1 200 mg every 3 wk or 400 mg every 6 wk 240 mg every 2 wk or 480 mg every 4 wk Approved for the treatment of pretreated pts with locally advanced UC or mUC who progressed on prior platinum-based tx or relapsed within 1 y of perioperative cisplatin tx Approved for the adjuvant treatment of pts with UC who are at high risk of recurrence after undergoing radical resection of UC Nivolumab3 PD-1 Immune Checkpoint Inhibitors Atezolizumab1 PD-L1 840 mg every 2 wk, 1,200 mg every 3 wk, or 1,680 mg every 4 wk Approved for the treatment of newly diagnosed pts with cisplatin-ineligible locally advanced UC or mUC and PD-L1+ tumors (tumor-infiltrating ICs covering ≥5% of the tumor area) or who are platinum ineligible Companion diagnostic: Ventana PD-L1 (SP142) Assay Approved for the treatment of pretreated pts with locally advanced UC or mUC who progressed on prior platinum-based tx or relapsed within 1 y of perioperative platinum-containing chemotherapy tx Approved for maintenance treatment of pts with locally advanced UC or mUC that has not progressed with first-line platinum-containing chemotherapy Avelumab2 PD-L1 800 mg every 2 wk Trop-2 10 mg/kg on d 1 and 8, every 21 d until disease progression or toxicity Approved for the treatment of pts with locally advanced UC or mUC who have had prior treatment with a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy regimen Sacituzumab govitecan7 Approved for the treatment of pretreated pts with locally advanced UC or mUC who have FGFR2 or FGFR3 genetic alterations and who progressed on prior platinum-based tx or relapsed within 1 y of perioperative platinum-containing chemotherapy tx Companion diagnostic: therascreen® FGFR RGQ RT-PCR Kit Erdafitinib5 FGFR 8 mg daily with an increase to 9 mg daily based on PO4 levels and tolerability at 14 to 21 d FGFR Inhibitors Therapeutic Targets, Indications, and Dosing Information
  • 2. 1. Tecentriq (atezolizumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034Orig1s042lbl.pdf. 2. Bavencio (avelumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s005lbl.pdf. 3. Opdivo (nivolumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125554s097lbledt.pdf. 4. Keytruda (pembrolizumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s113lbl.pdf. 5. Balversa (erdafitinib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212018s001lbl.pdf. 6. Padcev (enfortumab vedotin-ejfv) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf. 7. Trodelvy (sacituzumab govitecan-hziy) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf. 8. www.clinicaltrials.gov. Selected Ongoing Clinical Trials of Innovative Treatment Options in Urothelial Carcinoma8 First-Line Metastatic Second-Line Metastatic Bladder Preservation Adjuvant MIBC CheckMate -901 (NCT03036098) phase 3: nivolumab + ipilimumab vs nivolumab + chemo vs chemo NILE (NCT03682068) phase 3: durvalumab + chemo ± tremelimumab NCT04863885 phase 1/2: ipilimumab + nivolumab combined with sacituzumab govitecan for cisplatin-ineligible pts vs chemo NORSE (NCT03473743) phase 2: erdafitinib + cetrelimab vs erdafitinib THOR (NCT03390504) phase 3: erdafitinib vs chemo vs pembrolizumab in pts with selected FGFR mutations TROPHY-U-01 (NCT03547973) phase 2: sacituzumab govitecan TROPiCS-04 (NCT04527991) phase 3: sacituzumab govitecan vs chemo NMIBC Neoadjuvant SunRISe-2 (NCT04658862) phase 3: TAR-200 + cetrelimab vs gemcitabine/cisplatin or RT S1806 (NCT03775265) phase 3: atezolizumab ± CRT in localized MIBC AMBASSADOR (NCT03244384) phase 3: pembrolizumab vs observation IMvigor010 (NCT02450331) phase 3: atezolizumab vs observation ALBAN (NCT03799835) phase 3: atezolizumab + BCG vs BCG KEYNOTE-676 (NCT03711032) phase 3: SunRISe-1 (NCT04640623) phase 2b: TAR-200 + cetrelimab vs TAR-200 vs cetrelimab pembrolizumab + BCG vs BCG SWOG 1605 (NCT02844816) phase 2: atezolizumab monotherapy ENERGIZE (NCT03661320) phase 3: nivolumab + chemo or nivolumab + linrodostat (IDO1 inhibitor) + chemotherapy → immuno-oncology therapy after radical cystectomy vs chemotherapy KEYNOTE-866 (NCT03924856) phase 3: Perioperative pembrolizumab + neoadjuvant chemo vs perioperative placebo + neoadjuvant chemo NCT04209114 phase 3: neoadjuvant and adjuvant nivolumab + bempegaldesleukin vs nivolumab alone vs SOC in pts with MIBC who are cisplatin ineligible KEYNOTE-B15 (NCT04700124) phase 3: pembrolizumab + enfortumab vedotin NCT04241185 phase 3: pembrolizumab + CRT in MIBC A Snapshot of Approved Therapies and Ongoing Investigations in Urothelial Carcinoma Full abbreviations, accreditation, and disclosure information available at PeerView.com/RPD40
  • 3. Guide to Managing Adverse Events Associated With Therapies for Urothelial Carcinoma Therapeutic Targets, Current Status/Indication, and Dosing Information Full abbreviations, accreditation, and disclosure information available at PeerView.com/RPD40 • In general, checkpoint inhibitor therapy should be continued with close monitoring, with the exception of some neurologic, hematologic, and cardiac toxicities Minimal or no symptoms; diagnostic changes only Grade 1 • Hold checkpoint inhibitor therapy for most grade 2 toxicities • Consider resuming immunotherapy when symptoms and/or laboratory values revert to grade 1 or lower • Corticosteroids (initial dose of 0.5-1 mg/kg/d of prednisone or equivalent) may be administered Grade 3 toxicities • Hold checkpoint inhibitor therapy • Initiate high-dose corticosteroids (prednisone 1-2 mg/kg/d or methylprednisolone IV 1-2 mg/kg/d) • If symptoms do not improve with 48-72 hours of high-dose corticosteroids, infliximab may be offered for some toxicities • Taper corticosteroids over the course of at least 4-6 weeks • When symptoms and/or laboratory values revert to grade 1 or lower, rechallenging with immunotherapy may be offered; however, caution is advised, especially in those patients with early-onset irAEs; dose adjustments are not recommended Grade 4 toxicities • In general, permanent discontinuation of checkpoint inhibitor therapy is warranted, with the exception of endocrinopathies that have been controlled by hormone replacement Grade 2 Mild to moderate symptoms Severe or life-threatening symptoms Grades 3/4 Immune checkpoint inhibitors are associated with important clinical benefits, but general immunologic enhancement can also lead to a unique spectrum of immune-related adverse events (irAEs)1,2 irAEs are often diagnosed by exclusion; other causes should be ruled out (including AEs of other therapies used), but immunotherapy-related toxicity should always be included in the differential There should be a high level of suspicion that new symptoms are treatment related; early recognition, evaluation, and treatment of irAEs plus patient education are essential for best outcomes Depending on the severity of irAEs, management may require corticosteroid or other immunosuppressive treatment as well as interruption or discontinuation of therapy If appropriate, immunosuppressive treatment is used; patients generally recover from irAEs How should irAEs be diagnosed? What are the general recommendations for irAE management? What is the spectrum of potential irAEs? Pancreatitis, autoimmune diabetes Colitis Enteritis Encephalitis, aseptic meningitis Thyroiditis, hypothyroidism, hyperthyroidism Dry mouth, mucositis Hypophysitis Uveitis Pneumonitis Thrombocytopenia, anemia Hepatitis Adrenal insufficiency Nephritis Vasculitis Arthralgia Neuropathy Rash, vitiligo Myocarditis Any organ system can be affected; commonly occurring irAEs are pulmonary (pneumonitis), dermatologic (rash, pruritus, blisters, ulcers, vitiligo), gastrointestinal (diarrhea, enterocolitis, transaminitis, hepatitis, pancreatitis), and endocrine (thyroiditis, hypophysitis, adrenal insufficiency) Why do irAEs occur? “Taking the brakes off” of the immune system can help the body fight cancer, but it can also lead to toxicity from a “supercharged” immune system.
  • 4. Safety Management for FGFR Inhibitor Therapy8,9 Erdafitinib  Mucositis, other oral toxicities Oral  Monitor for toxicities  Refer to dermatology and podiatry as needed Skin and Nail  Dietary phosphate may require restriction  Individualized dietary plan from nutrition professional  Consider adding a non–calcium-containing phosphate binder (eg, sevelamer carbonate) Dietary FGF FGF FGF FGF FGFR HSPG FGF FGF FGFRL1 SEF SPRY FRS2 PLC-y DAG STAT GAB1 SOS GRB2 RAS RAF MEK ERK MKP3 MKP1 AKT PKC PI3K Nucleus Transcription of target genes Cytoplasm Extracellular PIP2 P P P P P P P P P P P P IP3 Plasma membrane Proliferation and survival Resistance to anticancer agents Neoangiogenesis FGFR alterations: Amplification (receptor overexpression) or mutation/translocation (ligand-independent signaling) FGF ligand: Amplification (autocrine) or ECM/stromal- cell release (paracrine) FGFR in UC3,4 FGFR Signaling Pathway7 FGFR is altered in 15% to 20% of advanced UC.5 Mutated FGFR3 is present in 37% of upper-tract UC.6 FGFRs are a family of receptor tyrosine kinases that are upregulated in multiple different cancers and are involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival; alterations in the FGFR gene, such as mutations and translocations, have been implicated in the pathogenesis of UC  Eye exams  Withhold for any occurrence of CSR or RPED  Discontinue permanently if CSR/ RPED symptoms do not resolve in 4 wk or if they escalate to grade 4 Ocular Guide to Managing Adverse Events Associated With Therapies for Urothelial Carcinoma Therapeutic Targets, Current Status/Indication, and Dosing Information Full abbreviations, accreditation, and disclosure information available at PeerView.com/RPD40
  • 5. Sacituzumab Govitecan Antibody–Drug Conjugates Antibody–drug conjugates (ADCs) are molecules composed of an antibody chosen based on its ability to target a tumor-specific protein linked to a cytotoxic payload or drug, enabling it to deliver a cytotoxic agent directly to the targeted cells while minimizing toxicity to healthy cells10 Enfortumab Vedotin Peripheral Neuropathy  Generally resolves/remains at grade 1 Hyperglycemia  Monitor blood glucose (patients with/at risk for diabetes or hyperglycemia) Maculopapular Diffuse Rash  Topical steroids  Antihistamines  Dose reductions/delays  Systemic corticosteroids (special cases) Diarrhea  Educate patients  Hydration with electrolytes  Anti-diarrheal medications  Best supportive care Safety Management for Antibody–Drug Conjugate Therapy11-13 1Binds to antigen 2Complex is internalized and traffics to lysosome 3Payload is released and causes cell death Neutropenia  Consider growth factor support  Dose reduction or hold Sacituzumab Govitecan Enfortumab Vedotin Target: Nectin-4, a type 1 transmembrane cell adhesion molecule overexpressed in epithelial cancers Linker: Protease cleavable Payload: MMAE Target: Trop-2, an epithelial cell-surface glycoprotein highly expressed in muscle-invasive disease Linker: Hydrolysable Payload: SN-38, the active metabolite of irinotecan 1. Postow MA et al. N Engl J Med. 2018;378:158-168. 2. Brahmer JR et al. J Clin Oncol. 2018;36:1714-1768. 3. https://tcga-data.nci.nih.gov/docs/publications/tcga. 4. Knowles MA et al. Nat Rev Cancer. 2015;15:25-41. 5. Rodriguez-Vida A et al. J Hematol Oncol. 2015;8:119. 6. Li Q et al. Curr Urol Rep. 2016;17:12. 7. Touat M et al. Clin Cancer Res. 2015;21:2684-2694. 8. Loriot Y et al. N Engl J Med. 2019;381:338-348. 9. Balversa (erdafitinib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212018s001lbl.pdf. 10. Parslow AC et al. Biomedicines. 2016;4:14. 11. Rosenberg JE et al. J Clin Oncol. 2019;37:2592-2600. 12. Loriot Y et al. Ann Oncol. 2020;31(suppl 4)s1142-s1215. 13. Petrylak DP et al. J Clin Oncol. 2020;38(suppl): Abstract 5027. Guide to Managing Adverse Events Associated With Therapies for Urothelial Carcinoma Therapeutic Targets, Current Status/Indication, and Dosing Information Full abbreviations, accreditation, and disclosure information available at PeerView.com/RPD40